Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Oracle Plans $45–$50 Billion Funding Push in 2026 to Expand Cloud and AI Infrastructure 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Instagram Outage Disrupts Thousands of U.S. Users 
Sam Altman Reaffirms OpenAI’s Long-Term Commitment to NVIDIA Amid Chip Report 
Nvidia Confirms Major OpenAI Investment Amid AI Funding Race 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
SoftBank and Intel Partner to Develop Next-Generation Memory Chips for AI Data Centers 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Amgen (NASDAQ: AMGN) is investing $200 million in its new technology and innovation center in Hyderabad, India, to enhance AI and data-driven drug development. CEO Robert Bradway, speaking at the site's inauguration, confirmed plans for further investments in the coming years.
The Hyderabad facility, announced last year, aims to accelerate medicine development through cutting-edge technology. By year-end, it is expected to employ 2,000 people, with 300 already on board, according to Som Chattopadhyay, Amgen's national executive for India.
Amgen’s expansion aligns with India’s growing role as the “pharmacy of the world,” attracting global pharmaceutical giants. The company’s presence in Hyderabad coincides with the BioAsia conference, where key executives from Amgen, Eli Lilly (NYSE: LLY), Novartis (SIX: NOVN), and leading Indian pharma firms will participate.
The U.S. and India recently initiated talks for a trade deal to strengthen collaboration in emerging technologies. U.S. Consul General in Hyderabad, Jennifer Larson, highlighted Amgen’s expansion as a prime example of this partnership. However, potential U.S. tariffs on pharmaceutical imports—reportedly 25% or higher—could impact Indian drugmakers, as the U.S. remains their largest market.
With Amgen’s strategic investment, India’s biotech sector continues to gain global attention, reinforcing its position as a key hub for pharmaceutical innovation.
